
    
      -  Patients receive bevacizumab, oxaliplatin, leucovorin, and 5-FU intravenously. The
           erlotinib is taken orally each day. One cycle of study therapy is 14 days. Cycles may be
           repeated unless there are intolerable side effects or the cancer worsens.

        -  Patients will undergo a tumor measurement evaluation following 3 cycles of study
           therapy, and then every 4 cycles thereafter.
    
  